Topical axitinib is a potent inhibitor of corneal neovascularization.

Background: This study evaluated the effects of topically applied axitinib, a tyrosine kinase inhibitor, in an experimental model of corneal neovascularization (CNV).

Methods: A total of 48 New Zealand rabbits were used. CNV was induced by placing five silk sutures in the upper cornea of one eye per rabbit.

New corneal neovascularization model in rabbits for angiogenesis research.

Purpose: To evaluate a new experimental model of suture-induced corneal neovascularization (NV) for angiogenesis research.

Methods: The new model was created in the right eye of 20 New Zealand rabbits using 5 interrupted silk sutures following an inverted triangle pattern. At different time points after suture placement, calibrated photographs were taken to quantify the corneal surface covered by the sutures (SCS) and the corneal NV response.

Inhibition of corneal neovascularization by topical bevacizumab (Anti-VEGF) and Sunitinib (Anti-VEGF and Anti-PDGF) in an animal model.

Purpose: To evaluate the effects of topically applied bevacizumab and sunitinib on experimentally induced corneal neovascularization.

Design: Experimental animal study.

Methods: Thirty-six New Zealand rabbits were involved.